For the first time, our data provide proof of concept for the combination of FLT3scFv/NKG2D-CAR T cells and gilteritinib as a synergistic therapy for relapsed/refractory FLT3mut+ AML. Here, KLRK1 is linked to acute myeloid leukemia.